Genome editing in cardiovascular diseases.

Area of Science:

• Biomedical Research
• Genetics
• Cardiovascular Science

Background:

• Genome-editing tools like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9 systems allow precise genomic manipulation.
• These technologies facilitate applications such as creating knockout alleles, introducing mutations, and inserting transgenes in cells and model organisms.

Purpose of the Study:

• To review the applications of genome-editing technology in cardiovascular disease research.
• To discuss the future prospects of in vivo genome-editing therapies for cardiovascular disorders.
• To identify current limitations hindering the full potential of cardiovascular genome editing.

Main Methods:

• Review of existing literature on genome-editing applications in biomedical research.
• Focus on studies within the cardiovascular field, including lipid metabolism, electrophysiology, and cardiomyopathies.
• Analysis of current and potential future therapeutic strategies using genome editing.

Main Results:

• Genome editing has significantly advanced the understanding of cardiovascular disorders.
• It has enabled the creation of diverse cellular and animal models for studying cardiovascular diseases.
• Genome editing holds promise for developing novel cardiovascular therapies.

Conclusions:

• Genome editing is a transformative technology in cardiovascular research, offering new avenues for understanding disease mechanisms.
• The development of in vivo genome-editing therapies presents a future frontier for treating cardiovascular conditions.
• Addressing existing limitations is crucial for realizing the full scientific and therapeutic impact of genome editing in cardiology.